Davita Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Davita Inc trades at $231.73 (market cap $14.92B), while Abrdn Physical Platinum Shares ETF trades at $15.03. The key difference: Davita Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| DVA | PPLT | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $235.71 | $25.23 |
52-Week Low | $103.87 | $11.78 |
Enterprise Value | $27.47B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
PPLT trades at $14.52, down 1.69% with a bearish technical outlook showing 15 sell signals versus 0 buy signals. The ETF recently underwent a 1:10 stock split effective May 18, 2026, which adjusted share count without changing the fund's underlying value. Platinum has underperformed other precious metals recently, creating potential catch-up trade opportunities according to market commentary.
The outlook remains cautious as platinum lags gold's rally, though some analysts see long-term potential. Key risks include precious metals volatility and correlation dynamics. Recent downgrades to 'Hold' suggest limited near-term upside after PPLT's 84-100% returns over the past year, requiring careful entry timing for new positions.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →